Study of DCR-PHXC-101 in Normal Healthy Volunteers and Patients With Primary Hyperoxaluria

Group A (HVs) Major Inclusion Criteria: * Willing and able to provide informed consent and comply with study requirements. * Male or female subjects between 18 and 55 years of age, inclusive. * Subject must have a body mass index (BMI) 19.0 to 32 kg/m2, inclusive. * Non-smokers, at least 1-month tobacco free, and willing to remain tobacco free through end of study (EOS). * Women of child bearing potential must have a negative pregnancy test, cannot be breastfeeding, and must be willing to use contraception. Group A (HVs) Major Exclusion Criteria: * Presence of any medical condition, including but not limited to: Severe intercurrent illness, known causes of active liver disease. * Routine or chronic use of more than 3 grams of acetaminophen (Tylenol) daily. * History of kidney stones. * Use of any investigational agent within 90 days before the first dose of study medication. * History of donation of more than 450 mL of blood within 90 days prior to dosing in the clinical research center or planned donation less than 30 days after receiving Investigational Medicinal Product (IMP). * Plasma or platelet donation within 7 days of dosing and through EOS. * History of reactions to an oligonucleotide-based therapy. * Males with female partners who are planning to attempt to become pregnant during this study or within 90 days after last dosing of IMP. * Plasma or platelet donation within 7 days of dosing and through EOS. Group B (PH1 and PH2 patients) Major Inclusion Criteria: *…